UY39263A - Compuestos de dihidroquinolinsulfonamida de ciclobutilo - Google Patents

Compuestos de dihidroquinolinsulfonamida de ciclobutilo

Info

Publication number
UY39263A
UY39263A UY0001039263A UY39263A UY39263A UY 39263 A UY39263 A UY 39263A UY 0001039263 A UY0001039263 A UY 0001039263A UY 39263 A UY39263 A UY 39263A UY 39263 A UY39263 A UY 39263A
Authority
UY
Uruguay
Prior art keywords
compounds
cyclobutyl
dihydroquinolinsulfonamide
formula
present
Prior art date
Application number
UY0001039263A
Other languages
English (en)
Inventor
C Milgram Benjamin
E Marx Isaac
Haoxuan Wang
H Cherney Alan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY39263A publication Critical patent/UY39263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de dihidroquinolinsulfonamida de ciclobutilo de Fórmula (I), un enantiómero, diastereoisómero, atropisómero del mismo, una mezcla de los mismos, o una sal farmacéuticamente aceptable del mismo, que inhibe los canales de sodio activados por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención. También se proporciona además una preparación atropi-selectiva de dichos compuestos de Fórmula (I), y un producto intermedio.
UY0001039263A 2020-06-10 2021-06-10 Compuestos de dihidroquinolinsulfonamida de ciclobutilo UY39263A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063037001P 2020-06-10 2020-06-10

Publications (1)

Publication Number Publication Date
UY39263A true UY39263A (es) 2021-11-30

Family

ID=76797115

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039263A UY39263A (es) 2020-06-10 2021-06-10 Compuestos de dihidroquinolinsulfonamida de ciclobutilo

Country Status (19)

Country Link
US (2) US20220306604A1 (es)
EP (1) EP4165024A1 (es)
JP (1) JP2021195368A (es)
KR (1) KR20230022996A (es)
CN (1) CN115697971A (es)
AR (1) AR122592A1 (es)
AU (1) AU2021288696A1 (es)
BR (1) BR112022025201A2 (es)
CA (1) CA3183889A1 (es)
CL (1) CL2022003499A1 (es)
CO (1) CO2022017903A2 (es)
CR (1) CR20220631A (es)
IL (1) IL298325A (es)
JO (1) JOP20220334A1 (es)
MX (1) MX2022015856A (es)
PE (1) PE20230860A1 (es)
TW (1) TW202214586A (es)
UY (1) UY39263A (es)
WO (1) WO2021252820A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014378A (es) 2021-06-04 2023-12-15 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio.
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) * 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
MA44066A (fr) * 2015-12-18 2018-10-24 Amgen Inc Composés sulfonamides de dihydroquinoline d'alcynyle
CR20180368A (es) * 2015-12-18 2018-09-28 Amgen Inc Compuestos de dihidroquinolinsulfonamida de alquilo
EP3440056A4 (en) * 2016-03-21 2019-11-27 The Scripps Research Institute PD (II) -CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C (SP3) H BINDING ACTIVATION

Also Published As

Publication number Publication date
CA3183889A1 (en) 2021-12-16
PE20230860A1 (es) 2023-05-30
CL2022003499A1 (es) 2023-08-04
JP2021195368A (ja) 2021-12-27
AR122592A1 (es) 2022-09-21
BR112022025201A2 (pt) 2023-02-28
AU2021288696A1 (en) 2022-12-15
MX2022015856A (es) 2023-01-24
CN115697971A (zh) 2023-02-03
KR20230022996A (ko) 2023-02-16
US20220306604A1 (en) 2022-09-29
EP4165024A1 (en) 2023-04-19
IL298325A (en) 2023-01-01
TW202214586A (zh) 2022-04-16
CO2022017903A2 (es) 2022-12-20
CR20220631A (es) 2023-01-23
JOP20220334A1 (ar) 2023-01-30
WO2021252820A1 (en) 2021-12-16
US20210387978A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
UY39263A (es) Compuestos de dihidroquinolinsulfonamida de ciclobutilo
UY39264A (es) Compuestos de dihidroquinolinsulfonamida de ciclopropilo
MX2022008066A (es) Compuestos triciclicos sustituidos.
CL2017002153A1 (es) Compuestos bicíclicos de sulfonamida cetona
CL2022000619A1 (es) Oxinitruro de piridina, método para su preparación y uso de este
MX2022006475A (es) Compuestos triciclicos sustituidos.
ES2939260T3 (es) Derivado de gamma-aminoácido tricíclico condensado, método de preparación del mismo y uso médico del mismo
ECSP066688A (es) Polimorfo cristalino de una sal de bisulfato de underivados de azepinoindol como agentes farmaceuticos antagonista del receptor de trombina
ES2179353T3 (es) Antagonistas muscarinicos.
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
CO2020011852A2 (es) Inhibidores de canales receptores de potencial transitorio de oxadiazol
DE69510192T2 (de) Substituierte cyclopentylaminderivate und deren verwendung als calcium-kanal antagonisten
MX2022006470A (es) Tiromimeticos novedosos.
CR20190147A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
AR127470A1 (es) Inhibidores de lrrk2
CL2023003223A1 (es) Derivado de fosfonilo, y composición y aplicación farmacéutica de este
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
CL2022001317A1 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma.
BR112022009705A2 (pt) Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
UY39799A (es) Compuestos de pirrolil–sulfonamida
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales
AR042480A1 (es) Derivados de la quinazolina para el trtamiento del crecimiento celular anormal